The European investment bank (EIB) and Fabentech, a French biopharmaceutical company specializing in the development and production of therapeutics against biological threats, have signed a €20 million financing under the HERA Invest mechanism. This €100 million initiative is part of the European Health Union and aims at supporting health emergency prevention and preparedness in Europe, particularly in response to deliberate or natural emergence of biological threats. This significant financing is the result of a thorough analysis of the project’ soundness and is a recognition of the quality of Fabentech’s product portfolio to improve the preparation of Europe against biological threats.
Fabentech’s innovative FabShield® technology platform relies on the production of broad-spectrum polyclonal antibody fragments, designed to neutralize deadly viruses and toxins, including their variants. By leveraging its integrated R&D and bioproduction capabilities, this technology aims to anticipate the development and production of medical countermeasures, ensuring a rapid and effective response in public health emergencies.
Strategic Funding for Global Impact
The €20 million secured through HERA Invest, a flagship initiative of the European Health Emergency Preparedness and Response Authority (HERA) will be strategically allocated to accelerate Fabentech’s growth in several key areas:
R&D: strengthening Fabentech’s R&D efforts with 6 ongoing programmes targeting top-priority toxins and viruses for biodefense and pandemic preparedness solutions.
Reinforcing and Scaling-up bio-production: by leveraging on Fabentech’s validated and robust FabShield® technology platform.
Market Expansion: bolstering marketing efforts to establish a stronger global presence in critical markets and strengthening Fabentech’s pharmaceutical operations to meet increasing international demand.
HERA Invest: Empowering Innovation in Health Security
HERA Invest is a €100 million top-up to the InvestEU programme, funded by the EU4Health programme. It is implemented by the EIB and supports projects that focus on pathogens with pandemic potential, chemical, biological, radiological, nuclear threats, and antimicrobial resistance.
"Backed by EU4Health, HERA Invest encourages innovation in pandemic and CBRN preparedness”, said Laurent Muschel Director-General of HERA. “Partnerships with biopharmaceutical companies like Fabentech, known for their cutting-edge immunotherapies, align with HERA's commitment to ensure better preparedness for future crises."
Ambroise Fayolle, Vice-President of the European Investment Bank, added: “Investment in innovative companies such as Fabentech is essential for strengthening health security in Europe. With the joint support of HERA and the EIB through HERA Invest, Europe finances projects that advance emergency medical treatment against the most serious biological threats. This funding will enable Fabentech to step up its work in this strategic area for Europe, strengthening our ability to respond to future health crises.”
A Commitment to Global Health and Safety
Fabentech is dedicated to collaborating closely with governments and healthcare organizations to develop effective medical countermeasures against highly pathogenic agents. Whether responding to natural outbreaks or deliberate biological attacks, Fabentech’s mission is to minimize the impact of these growing threats and safeguard public health on a global scale.
“We are honored to receive this support from HERA and the European Investment Bank,” said Sébastien Iva, CEO of Fabentech. “This funding reflects the confidence in our technology and our commitment to safeguarding populations from biological threats. It will allow us to accelerate our initiatives and broaden our impact on a global scale.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!